Myrobalan Therapeutics Welcomes New Leadership
Myrobalan Therapeutics has made a significant advancement by appointing Robin Kleiman, Ph.D., as its new Chief Scientific Officer. This decision underscores the company's ongoing commitment to pioneering innovative therapies aimed at restoring brain function in patients suffering from central nervous system (CNS) disorders. Dr. Kleiman's extensive experience in drug discovery is expected to catalyze the progress of Myrobalan's promising pipeline.
Introducing Dr. Robin Kleiman
Dr. Robin Kleiman joins Myrobalan Therapeutics with over twenty-five years of experience in neuroscience drug discovery. She will play a crucial role in enhancing the company's research initiatives. Having previously worked in various capacities including important roles at Alkermes, Inc., and Biogen, Dr. Kleiman has a track record that reflects her capability in transforming biological knowledge into viable therapeutic options.
Experience at Leading Biotechnology Firms
Before joining Myrobalan, Dr. Kleiman served as Vice President of CNS biology at Alkermes. There, she led several exploratory and early development programs, shaping the direction of research to address critical CNS issues. Her leadership was instrumental in establishing essential protocols that reinforced translatability in CNS research, ensuring that promising discoveries could be effectively transitioned from the lab to clinical settings.
Commitment to CNS Drug Development
Dr. Kleiman’s experience extends to her pivotal role at Biogen, where she established the Translational Cellular Sciences group. She was at the forefront of employing patient-derived technologies, enhancing their capacity for testing and developing novel CNS therapeutics. Her early career at Pfizer laid the groundwork for her extensive expertise, where she played a part in launching clinical trials aiming at groundbreaking mechanisms for CNS challenges.
Perspectives on Joining Myrobalan Therapeutics
Expressing her enthusiasm about her new role, Dr. Kleiman stated, “I am delighted to join Myrobalan Therapeutics and contribute to its mission of delivering transformative treatments to patients with severe CNS disorders.” Her dedication to the field aligns with Myrobalan’s vision of harnessing precision neuroscience to expedite the development of innovative therapeutics.
Educational Background
Dr. Kleiman earned her B.S. in Zoology from the University of Vermont, followed by a Ph.D. in Neuroscience from the University of Virginia. She further honed her expertise through postdoctoral training at the University of California, San Francisco (UCSF).
About Myrobalan Therapeutics
Myrobalan Therapeutics is a preclinical stage biotechnology company dedicated to creating oral neurorestorative therapies. Headquartered in Medford, Massachusetts, the company's primary goal is to tackle brain dysfunctions and CNS conditions comprehensively. By merging advanced knowledge of neurological processes with innovative drug discovery techniques, Myrobalan is positioned uniquely to develop candidates that can meet the significant medical needs present in this space. Their commitment extends to ensuring that patients suffering from degenerative CNS conditions can access safe and effective restorative treatments.
Frequently Asked Questions
Who is the newly appointed Chief Scientific Officer of Myrobalan?
The newly appointed Chief Scientific Officer is Robin Kleiman, Ph.D.
What experience does Dr. Kleiman bring to Myrobalan?
Dr. Kleiman brings over 25 years of experience in neuroscience drug discovery from her work in biotech and pharma sectors.
What is the primary focus of Myrobalan Therapeutics?
Myrobalan Therapeutics focuses on developing oral therapies aimed at reversing pathologies associated with CNS disorders.
Where can I find more information about Myrobalan Therapeutics?
More information can be found on Myrobalan's website at myrotx.com.
What educational background does Dr. Kleiman have?
Dr. Kleiman holds a B.S. in Zoology and a Ph.D. in Neuroscience, along with postdoctoral training at UCSF.
